37 results about "Colon inflammation" patented technology

A medicament for treating ulcerative colitis relates to medicaments for treating colitis, and is prepared by: selecting the following raw materials by weight: 13-17 g of radix astragali, 13-17 g of radix codonopsis, 13-17 g of bighead atractylodes rhizome, 9-15 g of semen cuscutae, 7-13 g of sophora bud, 9-15 g of sophora flower, 9-15 g of terminalia, 9-15 g of bletillastriata, 25-35 g of charred radix sanguisorbae, 13-17 g of radix paeoniae alba, 9-15 g of pomegranate rind, 9-15 g of Chinese gall, 9-15 g of red halloysite, 7-13 g of banksia rose, 7-13 g of camellia oleifera seeds, 7-13 g of cimicifugafoetida, 3-7 g of cinnamomum cassia and 3-7 g of coptis; cutting into segments or cutting into sheets or grinding into powder, adding 3000-4000 g of water, boiling until one third of water is left, filtering out residues to obtain the medicinal soup. The beneficial effect of the medicament comprise that: by employing oral and clysis, the medicament is capable of simultaneously treating principal and subordinate symptoms, and is fast in drug effect, safe, reliable, and relatively excellent in treatment effect; and 109 examples of clinical experiments show that the effective rate is 98.2%.

The invention provides a traditional Chinese medicine in forms of suppository, patch and ointment and capable of radically treating hemorrhoid, and the hemorrhoid medicine is prepared from specially-prepared tobacco leaves, sodium chloride, a Chinese herbal medicine with a trivial name of Pazicao and portulaca oleracea. The hemorrhoid medicine has efficacy of repairing material metabolism functions, improving organism immunity, relaxing blood vessels, resolving and releasing toxicity, activating blood and dissipating stasis, diminishing inflammation, relieving pain, stopping bleeding, resolving putridity and promoting tissue regeneration, and the like; and the hemorrhoid medicine has effects of stopping bleeding, relieving pain and dispersing swelling on proctocele bleeding, oedema, purulence and pain caused by various anorectal diseases; and the cure rate is 100%. Additionally, the hemorrhoid ointment also has special curative effect on colitis when being injected into colon inflammation positions. When sodium chloride and portulaca oleracea are removed from the medicine, the obtained medicine has short healing time and amazing curative effect when being attached to various wounds caused by cutters, rusty iron nails and traumatic injuries, and belongs to sovereign remedy for treating open injury caused by outside force. The medicine has auxiliary treatment on beriberi.

The invention discloses lactobacillus casei L511 capable of inhibiting growth of liver cancer tumors and application of the lactobacillus casei L511. The lactobacillus casei LSC-L511 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on January 14, 2022, and the preservation number of the lactobacillus casei LSC-L511 is CGMCC (China General Microbiological Culture Collection Center) NO.24309. The lactobacillus casei LSC-L511 is named as Lactobacillus casei LSC-L511. A single strain of the sorafenib has very strong capability of regulating polarization of macrophages, can significantly inhibit the progress of liver cancer, can enhance the treatment effect of sorafenib on liver cancer by inducing ferroptosis of liver cancer cells, and also has multiple functions and applications of relieving colitis, improving intestinal flora structure and short-chain fatty acid level and the like.

The invention relates to the field of traditional Chinese medicines, in particular to a medicament for treating acute and chronic colonitis, which is used for solving the problems of temporary relieving of symptoms, incapability of healing, large side effects and the like existing in the conventional colonitis treating medicament. Chinese medicinal raw materials prepared into active ingredients consist of the following components in parts by weight: 10-20 parts of astragalus, 15-20 parts of Chinese magnoliavine fruit, 10-15 parts of Chinese pulsatilla root, 10-15 parts of hairyvein agrimonia herb and bud, 10-15 parts of weeping forsythia, 5-10 parts of amomum fruit, 5-8 parts of fructus crataegi, 5-8 parts of medicated leaven and 2-5 parts of dried ginger. Cold and warm materials as well as ascending and descending materials supplement each other in a prescription, so that various types of acute and chronic colonitis can be cured in a short period of time, a remarkable curative effect is achieved, the curative rate is up to 90 percent, and relapse after curing is prevented; and moreover, the medicament belongs to a pure Chinese medicinal preparation, is low in cost, is easy to accept by patients, and is worthy of clinical popularization and application.

The invention provides an anthocyanin nanoparticle based on a marine polysaccharide carrier. The marine polysaccharide, food-derived fluorescent nanoparticle, and hyaluronic acid are used as a composite carrier to combine with anthocyanin. The preparation method is: S1, dissolving sodium alginate in phosphoric acid In salt-buffered saline, add EDC and HOBt and food-derived fluorescent nanoparticles in sequence to obtain a fluorescent-alginic acid complex; S2, adding the fluorescent-alginic acid complex to a mixture of DMF and DCM, then adding DIC and DMAP; S3, removing the solvent after adding anthocyanin and the hyaluronic acid; S4, removing unreacted small molecules, and freeze-drying. The present invention can improve the stability of anthocyanin, control the slow release of anthocyanin, has the characteristics of fluorescent tracer, can be used as a fluorescent marker for in vivo imaging of animal tissues and organs, and can also be targeted for delivery to the colon of animals to alleviate the symptoms induced by DSS. Inflammatory damage to the colon.

The invention discloses a brand new application of a compound shown in a formula 1, namely the compound is used for preparing a medicine for treating an inflammatory bowel disease (IBD) by inhibiting activation of NLRP3 inflammasome and maturation and release of IL-1beta. According to the present invention, the research results show that the compound represented by the formula 1 can inhibit the mouse colitis induced by dextran sulfate sodium salt (DSS), and the application mechanism of the compound represented by the formula 1 mainly comprises that the activation of the NLRP3 inflammasome is inhibited so as to reduce the release of IL-1beta so as to inhibit inflammation; by recording and analyzing the weight loss, the disease activity index (DAI) score and the colon shortening condition of a DSS-induced colitis model mouse and the expression condition of IL-1beta and the like in the mouse colon tissue, the inhibition effect of the compound in the formula 1 on the colitis disease of the DSS-induced mouse colitis model is evaluated.

The invention belongs to the field of biomedicine, and discloses the application of Lactobacillus johnsonii in the preparation of medicaments for preventing and / or treating inflammatory bowel disease, and a method for preventing and / or treating inflammatory bowel disease of oral probiotics comprising Lactobacillus johnsonii strains such as UMNLJ22. In the present invention, Lactobacillus johnsonii can significantly improve spleen hyperplasia, colon shortening, colonic mucosal hyperplasia and colon inflammatory response in the inflammatory bowel disease mouse model induced by Citrobacter rodentium, and it is found that Lactobacillus johnsonii can significantly Alleviate inflammatory bowel disease in mice, so as to be used for the development and preparation of medicaments for preventing and / or treating inflammatory bowel disease.

The invention discloses a microanaerobic bacterium for treating colon inflammation, and the microanaerobic bacterium is Helicobacter hepatica. The present invention also provides the application of the microanaerobic bacteria in the preparation of drugs for preventing and / or treating colon inflammation and the application in the preparation of drugs for preventing colon cancer. In the present invention, the inventors clearly proposed for the first time that Helicobacter helicobacter can treat inflammatory enteritis and prevent colon cancer. It provides important clinical value and reference significance for the intestinal flora to diagnose and treat colorectal cancer.